Astrazeneca Plc Share Price Today
(NASDAQ: AZN)

Name: Astrazeneca Plc Share Price Today (NASDAQ: AZN) - Astrazeneca Plc Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Astrazeneca Plc share price is $70.08 & ₹6,060.31 as on 28 Jan 2025, 2.30 'hrs' IST

$70.08

▲

1.02

(1.48%)

Market is closed - opens 8 PM, 28 Jan 2025

View live Astrazeneca Plc share price in Dollar and Rupees. Guide to invest in Astrazeneca Plc stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Astrazeneca Plc, along with analyst recommendations, forecasts, and comprehensive financials.

Astrazeneca Plc share price movements

Today's Low: $69.56
Today's High: $70.32
$70.08
0.74%
Downside
Day's Volatility :1.08%
Upside
0.34%
52 Weeks Low: $60.47
52 Weeks High: $87.68
$70.08
13.71%
Downside
52 Weeks Volatility :31.03%
Upside
20.07%

Astrazeneca Plc (AZN) Returns

Period	Astrazeneca Plc	Sector (Health Care)	Index (NASDAQ Composite)
3 Months	-6.83%	-0.8%	4.2%
6 Months	-10.04%	-1.6%	11.4%
1 Year	4.3%	5.9%	25.1%
3 Years	20.39%	13.1%	40.5%

Astrazeneca Plc (AZN) Key Statistics

in dollars & INR

Previous Close	$69.06
Open	$69.51
Today's High	$70.3173
Today's Low	$69.56
Market Capitalization	$211.7B
Today's Volume	$6.8M
52 Week High	$87.675
52 Week Low	$60.47
Revenue TTM	$51.2B
EBITDA	$18.4B
Earnings Per Share (EPS)	$2.08
PE Ratio	32.67
Dividend Yield	2.23%
Profit Margin	12.68%
Quarterly Earnings Growth YOY	0.03%
Return On Equity TTM	16.66%

How to invest in Astrazeneca Plc Stock (AZN) from India?

It is very easy for Indian residents to invest directly in Astrazeneca Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Astrazeneca Plc stock in both Indian Rupees (INR) and US Dollars (USD). Search for Astrazeneca Plc or AZN on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Astrazeneca Plc or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Astrazeneca Plc shares which would translate to 0.012 fractional shares of Astrazeneca Plc as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Astrazeneca Plc, in just a few clicks!

Returns in Astrazeneca Plc (AZN) for Indian investors in Rupees

The Astrazeneca Plc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Astrazeneca Plc investment value today

Current value as on today

₹1,08,322

Returns

₹8,322

(+8.32%)

Returns from Astrazeneca Plc Stock

₹4,301 (+4.3%)

Dollar Returns

₹4,021 (+4.02%)

Indian investors sentiment towards Astrazeneca Plc (AZN)

-42.84%

Period: Dec 28, 2024 to Jan 27, 2025. Change in 30 Days versus previous period

Investment in Astrazeneca Plc Shares from India has dropped by -42.84% over the past 30 days, indicating reduced transactional activity.

-24%

Period: Dec 28, 2024 to Jan 27, 2025. Change in 30 Days versus previous period

Search interest for Astrazeneca Plc Stock from India on INDmoney has decreased by -24% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Astrazeneca Plc Stock (AZN Ticker)

Name	Shares Held	Change in Shares	% of Assets
ICICI Prudential NASDAQ 100 Index Fund Direct Growth	7583	0.00	0.24%

Global Institutional Holdings in Astrazeneca Plc

T. Rowe Price Associates, Inc.
2.03%
PRIMECAP Management Company
1.35%
Wellington Management Company LLP
1.20%
Capital Research & Mgmt Co - Division 3
1.19%
FMR Inc
0.75%
Franklin Resources Inc
0.62%

Analyst Recommendation on Astrazeneca Plc

Buy

81%Buy

15%Hold

2%Sell

Based on 38 Wall street analysts offering stock ratings for Astrazeneca Plc(by analysts ranked 0 to 5 stars)

Based on 38 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Astrazeneca Plc Stock (AZN)

What analysts predicted

Upside of 22.88%

Target:

$86.12

Current:

$70.08

Insights on Astrazeneca Plc Stock (Ticker Symbol: AZN)

Price Movement
In the last 7 days, AZN stock has moved up by 3.1%
Increasing Revenue
AstraZeneca Plc has shown strong revenue growth over the last 7 quarters. The revenue increased from $10.87 billion to $13.56 billion, averaging an increase of 3.6% each quarter.
Decreasing Net Profit
Astrazeneca Plc has experienced a decline in net profit over the last three quarters. The net profit decreased from $2.17 billion to $1.42 billion, with an average decrease of 18.7% each quarter.
AZN vs LLY (1 yr)
In the last 1 year, Eli Lilly And Company has given 26.4% return, outperforming this stock by 22.0%
AZN vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 229.7% return, outperforming this stock by 211.5%
Price to Sales
Astrazeneca Plc has a Price-to-Sales Ratio of 25.6, meaning that investors are willing to pay $25.6 for every $1 of sales the company generates. In comparison, Eli Lilly And Company has a lower Price-to-Sales Ratio of 17.8, indicating that investors are paying less for its sales.

AZN Astrazeneca Plc Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$22.1B	↓ 1.67%
Net Income	$2.2B	↓ 28.19%
Net Profit Margin	9.76%	↓ 3.6%

	FY19	Y/Y Change
Revenue	$24.4B	↑ 10.38%
Net Income	$1.3B	↓ 38.05%
Net Profit Margin	5.47%	↓ 4.29%

	FY20	Y/Y Change
Revenue	$26.6B	↑ 9.16%
Net Income	$3.2B	↑ 139.4%
Net Profit Margin	12.01%	↑ 6.54%

	FY21	Y/Y Change
Revenue	$37.4B	↑ 40.58%
Net Income	$112.0M	↓ 96.5%
Net Profit Margin	0.3%	↓ 11.71%

	FY22	Y/Y Change
Revenue	$44.4B	↑ 18.53%
Net Income	$3.3B	↑ 2835.71%
Net Profit Margin	7.41%	↑ 7.11%

	FY23	Y/Y Change
Revenue	$45.8B	↑ 3.29%
Net Income	$6.0B	↑ 81.11%
Net Profit Margin	13.0%	↑ 5.59%

	Q2 FY23	Q/Q Change
Revenue	$11.4B	↑ 4.94%
Net Income	$1.8B	↑ 0.83%
Net Profit Margin	15.93%	↓ 0.64%

	Q3 FY23	Q/Q Change
Revenue	$11.5B	↑ 0.67%
Net Income	$1.4B	↓ 24.42%
Net Profit Margin	11.96%	↓ 3.97%

	Q4 FY23	Q/Q Change
Revenue	$12.0B	↑ 4.63%
Net Income	$960.0M	↓ 30.13%
Net Profit Margin	7.98%	↓ 3.98%

	Q1 FY24	Q/Q Change
Revenue	$12.7B	↑ 5.45%
Net Income	$2.2B	↑ 126.98%
Net Profit Margin	17.19%	↑ 9.21%

	Q2 FY24	Q/Q Change
Revenue	$12.9B	↑ 2.04%
Net Income	$1.9B	↓ 11.56%
Net Profit Margin	14.89%	↓ 2.3%

	Q3 FY24	Q/Q Change
Revenue	$13.6B	↑ 4.85%
Net Income	$1.4B	↓ 25.84%
Net Profit Margin	10.53%	↓ 4.36%

	FY18	Y/Y Change
Profit	$17.2B	↓ 5.47%

	FY19	Y/Y Change
Profit	$19.5B	↑ 13.46%

	FY20	Y/Y Change
Profit	$21.3B	↑ 9.53%

	FY21	Y/Y Change
Profit	$25.0B	↑ 17.18%

	FY22	Y/Y Change
Profit	$32.0B	↑ 27.94%

	FY23	Y/Y Change
Profit	$37.8B	↑ 18.18%

	Q2 FY23	Q/Q Change
Profit	$9.5B	↑ 5.37%

	Q3 FY23	Q/Q Change
Profit	$9.4B	↓ 0.62%

	Q4 FY23	Q/Q Change
Profit	$9.7B	↑ 3.39%

	Q1 FY24	Q/Q Change
Profit	$10.5B	↑ 7.67%

	Q2 FY24	Q/Q Change
Profit	$10.8B	↑ 2.81%

	Q3 FY24	Q/Q Change
Profit	$10.5B	↓ 2.52%

	FY18	Y/Y Change
Operating Cash Flow	$2.6B	↓ 26.83%
Investing Cash Flow	$963.0M	↓ 141.37%
Financing Cash Flow	$-2.0B	↓ 30.38%

	FY19	Y/Y Change
Operating Cash Flow	$3.0B	↑ 13.41%
Investing Cash Flow	$-657.0M	↓ 168.22%
Financing Cash Flow	$-1.8B	↓ 13.65%

	FY20	Y/Y Change
Operating Cash Flow	$4.8B	↑ 61.64%
Investing Cash Flow	$-285.0M	↓ 56.62%
Financing Cash Flow	$-2.2B	↑ 24.82%

	FY21	Y/Y Change
Operating Cash Flow	$6.0B	↑ 24.26%
Investing Cash Flow	$-11.1B	↑ 3780.0%
Financing Cash Flow	$3.6B	↓ 265.64%

	FY22	Y/Y Change
Operating Cash Flow	$9.8B	↑ 64.48%
Investing Cash Flow	$-3.0B	↓ 73.23%
Financing Cash Flow	$-6.8B	↓ 286.98%

	FY23	Y/Y Change
Operating Cash Flow	$10.3B	↑ 5.48%
Investing Cash Flow	$-4.1B	↑ 37.3%
Financing Cash Flow	$-6.6B	↓ 3.75%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$1.7B	↓ 45.16%
Investing Cash Flow	$-520.0M	↓ 58.27%
Financing Cash Flow	$-1.5B	↓ 25.21%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$3.1B	↑ 81.26%
Investing Cash Flow	$-1.2B	↑ 134.81%
Financing Cash Flow	$-2.7B	↑ 79.46%

	Q4 FY23	Q/Q Change
Operating Cash Flow	$2.4B	↓ 23.57%
Investing Cash Flow	$-1.1B	↓ 11.79%
Financing Cash Flow	$-291.0M	↓ 89.33%

	Q1 FY24	Q/Q Change
Operating Cash Flow	$2.5B	↑ 4.45%
Investing Cash Flow	$-2.4B	↑ 124.05%
Financing Cash Flow	$2.0B	↓ 796.91%

Astrazeneca Plc Technicals Summary

Sell

Neutral

Buy

Astrazeneca Plc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Astrazeneca Plc (AZN) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Astrazeneca Plc	6.88%	-10.04%	4.3%	20.39%	42.76%
Eli Lilly And Company	4.44%	2.27%	25.3%	229.34%	466.46%
Johnson & Johnson	6.66%	-5.23%	-4.06%	-11.26%	1.68%
Merck & Co. Inc.	-0.44%	-15.02%	-19.24%	20.2%	13.23%
Novo Nordisk A/s	2.08%	-32.28%	-19.73%	75.25%	187.53%
Abbvie Inc	0.4%	-5.29%	7.93%	29.23%	116.31%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Astrazeneca Plc	32.67	32.67	0.72	4.14	0.17	0.09	0.02	26.27
Eli Lilly And Company	81.34	81.34	0.71	12.98	0.65	0.14	0.01	15.83
Johnson & Johnson	24.33	24.33	0.86	9.96	0.21	0.08	0.03	29.14
Merck & Co. Inc.	20.48	20.48	0.07	7.68	0.28	0.11	0.03	17.58
Novo Nordisk A/s	26.92	26.92	1.28	23.06	0.89	0.21	0.02	27.07
Abbvie Inc	59.93	59.93	0.41	10.77	0.56	0.08	0.04	3.41

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Astrazeneca Plc	Buy	$211.7B	42.76%	32.67	12.68%
Eli Lilly And Company	Buy	$678.1B	466.46%	81.34	20.48%
Johnson & Johnson	Buy	$356.7B	1.68%	24.33	16.74%
Merck & Co. Inc.	Buy	$247.7B	13.23%	20.48	19.23%
Novo Nordisk A/s	Buy	$352.9B	187.53%	26.92	35.01%
Abbvie Inc	Buy	$305.0B	116.31%	59.93	9.22%

Astrazeneca Plc Dividend announcements

Astrazeneca Plc Dividends September, 2024
In the quarter ending September,2024. Astrazeneca Plc has declared dividend of $0.50
Read More

About Astrazeneca Plc

AstraZeneca plc is an English pharmaceutical company located in Cambridge. It is a multinational pharmaceutical and biotechnology firm based in the United Kingdom and Sweden. The company operates in over 100 countries and caters to the requirements of millions of people globally. Among the significant ailments covered by the company's product range are oncology, gastrointestinal, infectious, respiratory, and inflammatory disorders. Astra AB and Zeneca Group Plc amalgamated to establish AstraZeneca in 1999. Astra AB was founded in 1913 by 400 Swedish doctors. Zeneca Group PLC was created in 1993 when the British chemicals business ICI (formed by the amalgamation of four British chemical companies) demerged its medicines, agrochemicals, and specialist divisions to become Zeneca Group PLC. The merger is one of the world's largest pharmaceutical businesses, having purchased several corporations, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013), and Definiens (by MedImmune in 2014). The organisation undertakes research and development in three strategic locations: England, Sweden, and Maryland, United States. The Oxford–AstraZeneca vaccine was approved for use in India in January 2021, paving the way for a large-scale vaccination campaign in the world's second-most populous country. The Serum Institute of India later stated that the Oxford–AstraZeneca shot would be manufactured locally under the brand name COVISHIELD. Currently Astrazeneca Plc has a market cap of $270.68 Billion. It has a P.E ratio of 42.04. The shares of Astrazeneca Plc are trading at $68.2. .

Organization	Astrazeneca Plc
Employees	89900
CEO	Mr. Pascal Soriot D.V.M., M.B.A.
Industry	Health Technology

Management People of Astrazeneca Plc

Name	Title
Mr. Pascal Soriot D.V.M., M.B.A.	CEO & Executive Director
Dr. Aradhana Sarin M.D.	CFO & Executive Director
Ms. Pam P. Cheng	EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board
Mr. Andrew P. Barnett	Head of Investor Relations
Mr. Jeffrey Pott J.D.	CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board
Gonzalo Vina	Head of Global Media Relations
Dr. Ruud Dobber Ph.D.	Executive Vice-President of BioPharmaceuticals Business Unit
Dr. Susan Mary Galbraith M.D., Ph.D.	Executive Vice President of Oncology Research & Development
Ms. Iskra Reic	Executive Vice President of International
Mr. David Fredrickson	Executive Vice-President of Oncology Business Unit

Important FAQs about investing in AZN Stock from India :

What is Astrazeneca Plc share price today?

Astrazeneca Plc share price today stands at $70.08, Open: $69.51 ; Previous Close: $69.06 ; High: $70.32 ; Low: $69.56 ; 52 Week High: $87.68 ; 52 Week Low: $60.47. The stock opens at $69.51, after a previous close of $69.06. The stock reached a daily high of $70.32 and a low of $69.56, with a 52-week high of $87.68 and a 52-week low of $60.47.

Can Indians buy Astrazeneca Plc shares?

Yes, Indians can invest in the Astrazeneca Plc (AZN) from India.

With INDmoney, you can buy Astrazeneca Plc at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Astrazeneca Plc at zero transaction cost.

How can I buy Astrazeneca Plc shares from India?

It is very easy to buy Astrazeneca Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Astrazeneca Plc (AZN) be purchased?

Yes, you can buy fractional shares of Astrazeneca Plc with INDmoney app.

What are the documents required to start investing in Astrazeneca Plc stocks?

To start investing in Astrazeneca Plc, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.